Clinical Trial Update: PET/CT Imaging Study of the Safety and Diagnostic Performance of [68Ga]RM2 in Patients With Primary Prostate Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 PET/CT imaging study of [68Ga]RM2 in primary prostate cancer was terminated, with status indicating the trial has ended.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• 68Ga-RM2

Snippet

Sponsor: Life Molecular Imaging SA | Conditions: Prostate Cancer | Phase 1, Phase 2 | Status: TERMINATED